BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 35667922)

  • 21. Generation of a human induced pluripotent stem cell line derived from a Parkinson's disease patient carrying SNCA duplication.
    Suzuki H; Egawa N; Kondo T; Imamura K; Enami T; Tsukita K; Suga M; Shibukawa R; Okanishi Y; Uchiyama T; Inoue H; Takahashi R
    Stem Cell Res; 2020 May; 45():101828. PubMed ID: 32413791
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Transcriptomics analysis of human iPSC-derived dopaminergic neurons reveals a novel model for sporadic Parkinson's disease.
    Krauskopf J; Eggermont K; Madeiro Da Costa RF; Bohler S; Hauser D; Caiment F; de Kok TM; Verfaillie C; Kleinjans JC
    Mol Psychiatry; 2022 Oct; 27(10):4355-4367. PubMed ID: 35725899
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Advanced human iPSC-based preclinical model for Parkinson's disease with optogenetic alpha-synuclein aggregation.
    Kim MS; Ra EA; Kweon SH; Seo BA; Ko HS; Oh Y; Lee G
    Cell Stem Cell; 2023 Jul; 30(7):973-986.e11. PubMed ID: 37339636
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Surprising behavioral and neurochemical enhancements in mice with combined mutations linked to Parkinson's disease.
    Hennis MR; Marvin MA; Taylor CM; Goldberg MS
    Neurobiol Dis; 2014 Feb; 62():113-23. PubMed ID: 24075852
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of Parkinson's Disease through Personalized Medicine and Induced Pluripotent Stem Cells.
    Stoddard-Bennett T; Reijo Pera R
    Cells; 2019 Jan; 8(1):. PubMed ID: 30621042
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Higher vulnerability and stress sensitivity of neuronal precursor cells carrying an alpha-synuclein gene triplication.
    Flierl A; Oliveira LM; Falomir-Lockhart LJ; Mak SK; Hesley J; Soldner F; Arndt-Jovin DJ; Jaenisch R; Langston JW; Jovin TM; Schüle B
    PLoS One; 2014; 9(11):e112413. PubMed ID: 25390032
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Towards physiologically relevant human pluripotent stem cell (hPSC) models of Parkinson's disease.
    Coccia E; Ahfeldt T
    Stem Cell Res Ther; 2021 Apr; 12(1):253. PubMed ID: 33926571
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The multifaceted role of LRRK2 in Parkinson's disease: From human iPSC to organoids.
    Oun A; Sabogal-Guaqueta AM; Galuh S; Alexander A; Kortholt A; Dolga AM
    Neurobiol Dis; 2022 Oct; 173():105837. PubMed ID: 35963526
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Metabolic alterations in Parkinson's disease astrocytes.
    Sonninen TM; Hämäläinen RH; Koskuvi M; Oksanen M; Shakirzyanova A; Wojciechowski S; Puttonen K; Naumenko N; Goldsteins G; Laham-Karam N; Lehtonen M; Tavi P; Koistinaho J; Lehtonen Š
    Sci Rep; 2020 Sep; 10(1):14474. PubMed ID: 32879386
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Derivation, Characterization, and Neural Differentiation of Integration-Free Induced Pluripotent Stem Cell Lines from Parkinson's Disease Patients Carrying SNCA, LRRK2, PARK2, and GBA Mutations.
    Momcilovic O; Sivapatham R; Oron TR; Meyer M; Mooney S; Rao MS; Zeng X
    PLoS One; 2016; 11(5):e0154890. PubMed ID: 27191603
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Age-related pathological impairments in directly reprogrammed dopaminergic neurons derived from patients with idiopathic Parkinson's disease.
    Drouin-Ouellet J; Legault EM; Nilsson F; Pircs K; Bouquety J; Petit F; Shrigley S; Birtele M; Pereira M; Storm P; Sharma Y; Bruzelius A; Vuono R; Kele M; Stoker TB; Ottosson DR; Falk A; Jakobsson J; Barker RA; Parmar M
    Stem Cell Reports; 2022 Oct; 17(10):2203-2219. PubMed ID: 36150382
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impairment of proteasome and anti-oxidative pathways in the induced pluripotent stem cell model for sporadic Parkinson's disease.
    Chang KH; Lee-Chen GJ; Wu YR; Chen YJ; Lin JL; Li M; Chen IC; Lo YS; Wu HC; Chen CM
    Parkinsonism Relat Disord; 2016 Mar; 24():81-8. PubMed ID: 26797011
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Parkinson's disease: an update on preclinical studies of induced pluripotent stem cells.
    Valadez-Barba V; Juárez-Navarro K; Padilla-Camberos E; Díaz NF; Guerra-Mora JR; Díaz-Martínez NE
    Neurologia (Engl Ed); 2023; 38(9):681-694. PubMed ID: 37858889
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mitochondrial Phenotypes in Parkinson's Diseases-A Focus on Human iPSC-Derived Dopaminergic Neurons.
    Heger LM; Wise RM; Hees JT; Harbauer AB; Burbulla LF
    Cells; 2021 Dec; 10(12):. PubMed ID: 34943944
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Generation of three induced pluripotent stem cell lines from a Parkinson's disease patient with mutant PARKIN (p. C253Y).
    Tariq M; Liu H; Ibañez DP; Li Y; Chen S; Jiang M; Fan W; Zhao P; Luo Z; Wang D; Kanwal S
    Stem Cell Res; 2020 May; 45():101822. PubMed ID: 32387897
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Analysis of dopaminergic neuronal dysfunction in genetic and toxin-induced models of Parkinson's disease in Drosophila.
    Navarro JA; Heßner S; Yenisetti SC; Bayersdorfer F; Zhang L; Voigt A; Schneuwly S; Botella JA
    J Neurochem; 2014 Nov; 131(3):369-82. PubMed ID: 25040725
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ER Stress and Autophagic Perturbations Lead to Elevated Extracellular α-Synuclein in GBA-N370S Parkinson's iPSC-Derived Dopamine Neurons.
    Fernandes HJ; Hartfield EM; Christian HC; Emmanoulidou E; Zheng Y; Booth H; Bogetofte H; Lang C; Ryan BJ; Sardi SP; Badger J; Vowles J; Evetts S; Tofaris GK; Vekrellis K; Talbot K; Hu MT; James W; Cowley SA; Wade-Martins R
    Stem Cell Reports; 2016 Mar; 6(3):342-56. PubMed ID: 26905200
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Trib3 Is Elevated in Parkinson's Disease and Mediates Death in Parkinson's Disease Models.
    Aimé P; Sun X; Zareen N; Rao A; Berman Z; Volpicelli-Daley L; Bernd P; Crary JF; Levy OA; Greene LA
    J Neurosci; 2015 Jul; 35(30):10731-49. PubMed ID: 26224857
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Modeling Parkinson's Disease Using Induced Pluripotent Stem Cells.
    Hu X; Mao C; Fan L; Luo H; Hu Z; Zhang S; Yang Z; Zheng H; Sun H; Fan Y; Yang J; Shi C; Xu Y
    Stem Cells Int; 2020; 2020():1061470. PubMed ID: 32256606
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Back and to the Future: From Neurotoxin-Induced to Human Parkinson's Disease Models.
    Airavaara M; Parkkinen I; Konovalova J; Albert K; Chmielarz P; Domanskyi A
    Curr Protoc Neurosci; 2020 Mar; 91(1):e88. PubMed ID: 32049438
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.